QuidelOrtho Corp (QDEL)
36.45
-0.87
(-2.33%)
USD |
NASDAQ |
Jun 14, 16:00
36.45
0.00 (0.00%)
After-Hours: 20:00
QuidelOrtho Research and Development Expense (Annual): 246.80M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 246.80M |
| December 31, 2022 | 190.50M |
| December 31, 2021 | 95.70M |
| December 31, 2020 | 84.29M |
| December 31, 2019 | 52.55M |
| December 31, 2018 | 51.65M |
| December 31, 2017 | 33.64M |
| December 31, 2016 | 38.67M |
| December 31, 2015 | 35.51M |
| December 31, 2014 | 37.91M |
| December 31, 2013 | 34.19M |
| December 31, 2012 | 27.72M |
| December 31, 2011 | 26.32M |
| December 31, 2010 | 23.70M |
| Date | Value |
|---|---|
| December 31, 2009 | 12.53M |
| December 31, 2008 | 11.15M |
| December 31, 2007 | 12.86M |
| December 31, 2006 | 13.05M |
| December 31, 2005 | 12.83M |
| December 31, 2004 | 11.34M |
| December 31, 2003 | 8.465M |
| December 31, 2002 | 6.748M |
| December 31, 2001 | 6.203M |
| December 31, 2000 | 7.046M |
| December 31, 1999 | 5.60M |
| March 31, 1999 | 7.90M |
| March 31, 1998 | 7.90M |
| March 31, 1997 | 6.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
52.55M
Minimum
2019
246.80M
Maximum
2023
133.97M
Average
95.70M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Boston Scientific Corp | 1.414B |
| Perspective Therapeutics Inc | 21.31M |
| Xtant Medical Holdings Inc | 1.336M |
| Asensus Surgical Inc | 37.02M |
| Catheter Precision Inc | 0.475M |